Surrozen, Inc. (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Purchases 1,034,482 Shares

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III purchased 1,034,482 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The stock was bought at an average price of $11.60 per share, for a total transaction of $11,999,991.20. Following the transaction, the insider now directly owns 795,411 shares in the company, valued at $9,226,767.60. This trade represents a -432.71 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Surrozen Price Performance

NASDAQ:SRZN opened at $11.01 on Friday. Surrozen, Inc. has a 12-month low of $6.00 and a 12-month high of $18.17. The firm has a 50-day moving average price of $11.37 and a 200 day moving average price of $10.94.

Wall Street Analysts Forecast Growth

SRZN has been the subject of several recent research reports. Guggenheim upgraded shares of Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 target price for the company in a report on Friday, January 3rd. HC Wainwright initiated coverage on Surrozen in a research note on Thursday, January 30th. They set a “buy” rating and a $32.00 price target for the company.

Institutional Trading of Surrozen

Large investors have recently made changes to their positions in the business. Geode Capital Management LLC boosted its position in Surrozen by 26.1% in the 4th quarter. Geode Capital Management LLC now owns 22,391 shares of the company’s stock valued at $321,000 after buying an additional 4,630 shares during the last quarter. Nantahala Capital Management LLC increased its position in shares of Surrozen by 4.7% during the 4th quarter. Nantahala Capital Management LLC now owns 196,023 shares of the company’s stock worth $2,813,000 after purchasing an additional 8,817 shares during the last quarter. Stonepine Capital Management LLC increased its holdings in Surrozen by 24.7% during the fourth quarter. Stonepine Capital Management LLC now owns 137,200 shares of the company’s stock worth $1,969,000 after buying an additional 27,200 shares during the last quarter. Trustees of Columbia University in the City of New York bought a new stake in Surrozen in the fourth quarter valued at approximately $688,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in Surrozen during the 4th quarter valued at $928,000. Institutional investors own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.